{"slideshow_credits": null, "snippet": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs....", "abstract": "Editorial rebukes Congress for merely censuring Mylan's chief executive for significantly raising price of EpiPens instead of directly addressing issue of rising drug costs; calls for empowering Medicare to negotiate prices with drug makers and making it easier for generic drug makers to bring cheaper version to market.", "section_name": "Opinion", "print_page": "30", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "web_url": "http://www.nytimes.com/2016/09/22/opinion/the-epipen-outrage-continues.html", "lead_paragraph": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs.", "headline": {"print_headline": "The EpiPen Outrage Continues", "main": "The EpiPen Outrage Continues", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "57e32b7995d0e021d7987a0a", "word_count": "526", "multimedia": [{"height": 126, "url": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 600, "url": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "600"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-09-22T04:00:00+0000", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Epinephrine (Drug)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Generic Brands and Products", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Inventions and Patents", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Lobbying and Lobbyists", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Mylan Inc", "is_major": "Y", "rank": "7"}, {"name": "subject", "value": "Antitrust Laws and Competition Issues", "is_major": "N", "rank": "8"}, {"name": "subject", "value": "Medicare", "is_major": "Y", "rank": "9"}, {"name": "subject", "value": "Editorials", "is_major": "Y", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}